OncoMatch/Clinical Trials/NCT07221149
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
Is NCT07221149 recruiting? Yes, currently enrolling (Sep 2026). This Phase 2/3 trial studies multiple treatments including Pumitamig and Folfox for untreated advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma.
Treatment: Pumitamig · Folfox · Capox · Nivolumab — The purpose of this study is to evaluate the safety and efficacy of Pumitamig in combination with chemotherapy versus Nivolumab in combination with chemotherapy in participants with previously untreated advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Other
Cancer type
Gastric Cancer
Esophageal Carcinoma
Biomarker criteria
Required: HER2 (ERBB2) wild-type
documented human epidermal growth factor receptor 2 (HER2)-negative cancer, as determined according to local guidelines
Prior therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Local Institution - 0284 · Phoenix, Arizona
- Local Institution - 0437 · Los Angeles, California
- University of California, Irvine (UCI) Health - UC Irvine Medical Center · Orange, California
- Local Institution - 0428 · San Francisco, California
- Florida Cancer Specialists - South · Fort Myers, Florida
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07221149 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require ERBB2?
Yes, ERBB2 wild-type is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages